Buy Yatharth Hospital & Trauma Care Ltd for the Target Rs.1,050 by Choice Institutional Equities
Business Overview:
YATHARTH is a leading hospital network in North India, operating seven multi-specialty hospitals with a strong footprint across the Delhi-NCR region. Since FY21, the company has expanded its capacity from 1,100 beds to +2,500 beds as of Q4FY26, while having an occupancy rate of 71% and achieving an ARPOB of INR 33,283. Looking ahead, YATHARTH plans to scale up its capacity to more than 3,000 beds by FY28E, primarily within Delhi-NCR. Over this period, the company is targeting a revenue CAGR of approximately 30%, while sustaining a EBITDA margin of around 25%.
Can YATHARTH’s cluster-based expansion strategy drive sustained long-term growth?
YATHARTH has successfully built dominant healthcare clusters across Noida and Faridabad and is now replicating this model in Gurugram and other North Indian markets. The strategy allows the company to leverage brand recognition, doctor recruitment, referral networks, and operational synergies across multiple hospitals within the same geography. Management expects to scale beyond 5,000 beds ahead of schedule, with nearly 70% of future expansion likely through acquisitions in proven healthcare markets. This disciplined and asset-focused approach reduces execution risks while providing a strong runway for market share gains, revenue growth, and operating leverage over the coming years.
Can new hospitals and acquisitions meaningfully enhance profitability?
The recently launched hospitals in Delhi and Faridabad, along with the Agra acquisition, are ramping up faster than management expectations. These facilities already contributed around 11% of Q4 revenue and are reporting encouraging occupancies, healthy ARPOBs, and favorable patient mixes. Agra is already profitable with double-digit EBITDA margins, while Delhi and Faridabad are expected to achieve EBITDA breakeven within 12–15 months
Will premiumization and specialty expansion support higher ARPOB growth?
YATHARTH continues to improve its revenue mix through increasing contributions from oncology, robotic surgeries, bone marrow transplants and international patients. Mature hospitals such as Greater Noida and Noida Extension have delivered strong ARPOB growth, while newer facilities are already operating at premium realization levels. The upcoming Gurugram hospital is expected to generate ARPOB exceeding INR50,000, supported by cash-paying, insured, and international patients.
Can medical tourism and international patient inflows become a key growth driver?
YATHARTH is increasingly positioning itself as a destination for medical value travel through international outreach programs, overseas partnerships, and its association with the newly operational Noida International Airport. International patient volumes are already contributing to ARPOB growth at key hospitals, particularly in Noida and Greater Noida. The company is also expanding its presence in Africa, the Middle East, and CIS countries through medical centres and outreach initiatives. As connectivity improves and specialized services expand, medical tourism could become an important source of high-margin revenue and longterm growth.
Why invest in YATHARTH?
YATHARTH revenue grew 36% in FY26 while maintaining EBITDA margins above 24%, despite adding nearly 1,000 beds. The company aims to expand from over 3,200 announced beds to 5,000 beds within three years, supported by a proven cluster-based strategy across NCR and North India. New hospitals in Delhi, Faridabad, and Agra are ramping up faster than expected, while premium assets such as Gurugram are expected to drive higher ARPOB and margins. Strong cash generation, a net cash balance sheet, rising medical tourism, improving payer mix, and management’s confidence of surpassing FY26 growth rates provide strong visibility for sustained earnings growth
Recommendation:
We currently have a ‘BUY’ rating on the stock with a target price of INR 1,050.
Key Risks:
* Competition: The rise of new or well-established competitors in the healthcare sector could erode YATHARTH’s market share and reduce patient inflow, affecting the hospital’s growth and sustainability
* Operational Challenges: The planned expansion of bed capacity to 3,000 beds could pose operational challenges
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
